NEW YORK & BRITISH COLUMBIA, Canada--(BUSINESS WIRE)--Royalty Pharma and InNexus Biotechnology Inc. (TSX Venture:IXS) (OTCBB:IXSBF), today announced that Royalty Pharma would purchase a royalty interest in up to two products targeting cancer based on InNexus’ Dynamic Cross Linking (DXL™) antibody enhancement technology.
